STAQ Pharma Inc. recalled FentaNYL Citrate PF on October 9, 2025, due to incorrect or missing lot and expiration dates. The injection, distributed nationwide, poses a high hazard risk. Consumers and healthcare providers should stop using the product immediately.
Labeling: Incorrect or Missing Lot and/or Exp Date
Consumers and healthcare providers should stop using this product immediately. Contact STAQ Pharma, Inc. or your healthcare provider for guidance. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
FentaNYL Citrate PF comes in a 50 mL syringe with an NDC of 73177-0102-05. The recall affects specific lots including 25102464B, 25102370A, and 25102369A.
The recall stems from labeling errors related to incorrect or missing lot numbers and expiration dates. This could lead to the administration of expired or ineffective medication, which poses significant health risks.
No specific incidents have been reported. However, the labeling issues could potentially affect patient safety.
Stop using the product immediately. Contact STAQ Pharma or consult your healthcare provider for further guidance.
For assistance, call STAQ Pharma at 1-800-XXX-XXXX or visit their website at www.staqpharma.com for more information.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.